Skip to content

Effects of a Structured Education Program on Blood Pressure in Essential Hypertensive Patients

Effects of a Structured Education Program on Blood Pressure in Essential Hypertensive Patients and Effects of a Reminder Program for Physicians to Guide Optimal Therapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00453037
Acronym
herzleben
Enrollment
256
Registered
2007-03-28
Start date
2007-03-31
Completion date
2010-12-31
Last updated
2011-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

hypertension, self measurement of blood pressure, education program, life style

Brief summary

The purpose of this study is to evaluate the effects of a structured educational program for hypertensive patients. The program was developed at the University of Dusseldorf, Germany. The contents of the program are as follows: teaching of the background of hypertension, techniques of self estimation of blood pressure, life style and dietary habits, some information concerning the different pharmacological properties to treat hypertension

Detailed description

see brief description section

Interventions

structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program

BEHAVIORALparticipation in the educational program after 6 months

Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group

Sponsors

Medical University of Graz
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Intellectual and physical ability to attend teaching program, * Capability to do and document blood pressure self-measurement, * Systolic blood pressure \>160 and/or diastolic blood pressure \>95 mmHg, * At least 3 months of preexisting medicamentous anti-hypertensive treatment, * 15% or higher risc in New Zealand Risc Scale

Exclusion criteria

* Failing inclusion criteria

Design outcomes

Primary

MeasureTime frame
Blood pressure at 6 and 12 months of follow up following the educational process1 year

Secondary

MeasureTime frame
morbidity on different cardiovascular and cerebrovascular diseases1 year

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026